Noha Mousaad Elemam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Noha Mousaad Elemam has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Azzam Al Maghazachi
Sharjah Institute for Medical Research, University of Sharjah
22 shared publications - Mahmood Yaseen Hachim
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai P.O. Box 505055, United Arab Emirates
13 shared publications - Iman Mamdouh Talaat
Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates
11 shared publications - Rifat Hamoudi
Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
9 shared publications - Rana Ahmed Youness
Molecular Biology and Biochemistry, Molecular Genetics Research Team (MGRT), Faculty of Biotechnology, German International University, Cairo, Egypt
7 shared publications - Ahmed Ihab Abdelaziz
School of Medicine, Newgiza University (NGU), Giza 12577, Egypt
6 shared publications
Latest Publications
- 11 October 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (10) , e70237
Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity
Colorectal cancer (CRC) remains a global health concern and a leading cause of cancer mortality, where therapeutic resistance persists as the central barrier to sustained response. Most conventional therapies rely on apoptosis, but CRC frequently resists through p53 alterations, anti‐apoptotic BCL‐2 upregulation, and drug efflux mechanisms. Here, we explore unconventional cell death pathways, focusing on ferroptosis, as a strategy to overcome apoptosis‐dependent therapeutic resistance in CRC. We discussed the molecular mechanisms of ferroptosis, including GPX4 blockade, iron dysregulation, and lipid metabolism remodeling, and emphasized their implications for drug‐resistant CRC. Then, necroptosis, pyroptosis, and autophagy were discussed in relation to their crosstalk with ferroptosis. Preclinical models show that ferroptosis inducers (e.g., erastin, RSL3, talaroconvolutin) selectively kill chemoresistant CRC, including KRAS‐mutant CRC, and potentiate the efficacy of conventional regimens. The therapeutic duality of autophagy, pyroptosis, and necroptosis in CRC is discussed, with emphasis on ferroptosis's ability to circumvent traditional mechanisms of resistance. Yet, clinical translation is hindered by insufficient pharmacokinetics, systemic toxicity, limited biomarker availability, tumor heterogeneity, compensatory antioxidant pathways, and the need for safer delivery platforms. We propose that ferroptosis is most likely to enter CRC therapy through rational combinations, biomarker‐guided patient selection, and tumor‐targeted delivery platforms rather than as a stand‐alone cytotoxic strategy.
- 11 October 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (10) , e70237
Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity
Colorectal cancer (CRC) remains a global health concern and a leading cause of cancer mortality, where therapeutic resistance persists as the central barrier to sustained response. Most conventional therapies rely on apoptosis, but CRC frequently resists through p53 alterations, anti‐apoptotic BCL‐2 upregulation, and drug efflux mechanisms. Here, we explore unconventional cell death pathways, focusing on ferroptosis, as a strategy to overcome apoptosis‐dependent therapeutic resistance in CRC. We discussed the molecular mechanisms of ferroptosis, including GPX4 blockade, iron dysregulation, and lipid metabolism remodeling, and emphasized their implications for drug‐resistant CRC. Then, necroptosis, pyroptosis, and autophagy were discussed in relation to their crosstalk with ferroptosis. Preclinical models show that ferroptosis inducers (e.g., erastin, RSL3, talaroconvolutin) selectively kill chemoresistant CRC, including KRAS‐mutant CRC, and potentiate the efficacy of conventional regimens. The therapeutic duality of autophagy, pyroptosis, and necroptosis in CRC is discussed, with emphasis on ferroptosis's ability to circumvent traditional mechanisms of resistance. Yet, clinical translation is hindered by insufficient pharmacokinetics, systemic toxicity, limited biomarker availability, tumor heterogeneity, compensatory antioxidant pathways, and the need for safer delivery platforms. We propose that ferroptosis is most likely to enter CRC therapy through rational combinations, biomarker‐guided patient selection, and tumor‐targeted delivery platforms rather than as a stand‐alone cytotoxic strategy.
- Open Access
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1887815
Long non-coding RNAs in glioblastoma: from molecular drivers to therapeutic targets
Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults and remains associated with poor clinical outcomes despite advances in surgical resection, radiotherapy, and temozolomide-based chemotherapy. Its remarkable molecular heterogeneity, highly immunosuppressive tumor microenvironment, and intrinsic therapeutic resistance continue to limit the effectiveness of current treatment strategies. Long non-coding RNAs (lncRNAs), transcripts exceeding 200 nucleotides in length that lack protein-coding capacity, have emerged as critical regulators of GBM biology through transcriptional, post-transcriptional, and epigenetic mechanisms. Acting as competing endogenous RNAs, chromatin modifiers, molecular scaffolds, and regulators of RNA-binding proteins, lncRNAs orchestrate key oncogenic pathways controlling proliferation, invasion, angiogenesis, stemness, metabolic reprogramming, immune evasion, and resistance to chemotherapy and radiotherapy. This review provides a comprehensive overview of lncRNA biogenesis, classification, and mechanisms of action, followed by an updated synthesis of oncogenic and tumor-suppressive lncRNAs implicated in GBM progression. Particular emphasis is placed on emerging evidence demonstrating how immunophenotype-related lncRNAs regulate immune cell infiltration, immune checkpoint signaling, and the immunosuppressive glioblastoma microenvironment, highlighting their potential to improve patient stratification and guide immunotherapeutic approaches. We also discuss the growing clinical utility of lncRNAs as diagnostic, prognostic, and predictive biomarkers, including circulating lncRNAs and lncRNA-based molecular signatures. Finally, we examine current and emerging therapeutic strategies targeting lncRNAs, including nanoparticle-mediated delivery systems designed to overcome the blood-brain barrier. Advances in single-cell and spatial transcriptomic technologies are further expanding our understanding of lncRNA-mediated regulatory networks and intratumoral heterogeneity, supporting the development of precision medicine strategies. Collectively, lncRNAs represent promising biomarkers and therapeutic targets with significant potential to improve the diagnosis, prognosis, and treatment of glioblastoma.
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1887815
Open AccessLong non-coding RNAs in glioblastoma: from molecular drivers to therapeutic targets
Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults and remains associated with poor clinical outcomes despite advances in surgical resection, radiotherapy, and temozolomide-based chemotherapy. Its remarkable molecular heterogeneity, highly immunosuppressive tumor microenvironment, and intrinsic therapeutic resistance continue to limit the effectiveness of current treatment strategies. Long non-coding RNAs (lncRNAs), transcripts exceeding 200 nucleotides in length that lack protein-coding capacity, have emerged as critical regulators of GBM biology through transcriptional, post-transcriptional, and epigenetic mechanisms. Acting as competing endogenous RNAs, chromatin modifiers, molecular scaffolds, and regulators of RNA-binding proteins, lncRNAs orchestrate key oncogenic pathways controlling proliferation, invasion, angiogenesis, stemness, metabolic reprogramming, immune evasion, and resistance to chemotherapy and radiotherapy. This review provides a comprehensive overview of lncRNA biogenesis, classification, and mechanisms of action, followed by an updated synthesis of oncogenic and tumor-suppressive lncRNAs implicated in GBM progression. Particular emphasis is placed on emerging evidence demonstrating how immunophenotype-related lncRNAs regulate immune cell infiltration, immune checkpoint signaling, and the immunosuppressive glioblastoma microenvironment, highlighting their potential to improve patient stratification and guide immunotherapeutic approaches. We also discuss the growing clinical utility of lncRNAs as diagnostic, prognostic, and predictive biomarkers, including circulating lncRNAs and lncRNA-based molecular signatures. Finally, we examine current and emerging therapeutic strategies targeting lncRNAs, including nanoparticle-mediated delivery systems designed to overcome the blood-brain barrier. Advances in single-cell and spatial transcriptomic technologies are further expanding our understanding of lncRNA-mediated regulatory networks and intratumoral heterogeneity, supporting the development of precision medicine strategies. Collectively, lncRNAs represent promising biomarkers and therapeutic targets with significant potential to improve the diagnosis, prognosis, and treatment of glioblastoma.
- 1 October 2025
- Published by Springer Nature
- p. 451-480
Chemokines and Chemokine Receptors in Cancer: An Update
- 1 October 2025
- Published by Springer Nature
- p. 451-480
Chemokines and Chemokine Receptors in Cancer: An Update
- Open Access
Tumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies
Pediatric oral rhabdomyosarcoma (RMS) is a rare and aggressive cancer of the head and neck, characterized by a complex and mostly immunosuppressive tumor–immune microenvironment. Unlike adult cancers, pediatric RMS typically exhibits a “cold” immune profile, characterized by minimal T-cell infiltration, a low mutational burden, and resistance to immune checkpoint blockade. The tumor’s location in the oral cavity adds difficulty to treatment because of anatomical and functional limitations. Additionally, the presence of fusion oncogenes, such as PAX3:FOXO1, hampers immunogenicity and treatment response by disrupting antigen presentation and reducing immune cell infiltration. Advances in immuno-oncology have introduced new strategies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) therapies, cancer vaccines, and oncolytic viruses. However, these approaches face specific challenges in the pediatric population due to developmental immune factors. This narrative review highlights recent findings on the immunobiology of pediatric oral RMS, focusing on tumor–immune interactions and their impact on disease progression and treatment resistance. We reviewed the cellular components of the TIME, the mechanisms of immune evasion, and the expression of immune checkpoints, including PD-L1 and B7-H3. Emerging immunotherapies, including CAR-T, CAR-NK, and CAR-CIK cell therapies; checkpoint inhibitors; oncolytic viruses; and cancer vaccines, are discussed, with an emphasis on their current limitations and potential to transform the pediatric RMS immune landscape.
Open AccessTumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies
Pediatric oral rhabdomyosarcoma (RMS) is a rare and aggressive cancer of the head and neck, characterized by a complex and mostly immunosuppressive tumor–immune microenvironment. Unlike adult cancers, pediatric RMS typically exhibits a “cold” immune profile, characterized by minimal T-cell infiltration, a low mutational burden, and resistance to immune checkpoint blockade. The tumor’s location in the oral cavity adds difficulty to treatment because of anatomical and functional limitations. Additionally, the presence of fusion oncogenes, such as PAX3:FOXO1, hampers immunogenicity and treatment response by disrupting antigen presentation and reducing immune cell infiltration. Advances in immuno-oncology have introduced new strategies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) therapies, cancer vaccines, and oncolytic viruses. However, these approaches face specific challenges in the pediatric population due to developmental immune factors. This narrative review highlights recent findings on the immunobiology of pediatric oral RMS, focusing on tumor–immune interactions and their impact on disease progression and treatment resistance. We reviewed the cellular components of the TIME, the mechanisms of immune evasion, and the expression of immune checkpoints, including PD-L1 and B7-H3. Emerging immunotherapies, including CAR-T, CAR-NK, and CAR-CIK cell therapies; checkpoint inhibitors; oncolytic viruses; and cancer vaccines, are discussed, with an emphasis on their current limitations and potential to transform the pediatric RMS immune landscape.
- Open Access
- 23 March 2025
- Published by Elsevier in Translational Oncology
- Vol. 55, 102365
In-vitro immune-modulation of triple-negative breast cancer through targeting miR-30a-5p/MALAT1 axis using nano-PDT combinational approach
- 23 March 2025
- Published by Elsevier in Translational Oncology
- Vol. 55, 102365
Open AccessIn-vitro immune-modulation of triple-negative breast cancer through targeting miR-30a-5p/MALAT1 axis using nano-PDT combinational approach
- Open Access
- 26 February 2025
- Published by Elsevier in Translational Oncology
- Vol. 54, 102329
MIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies
- 26 February 2025
- Published by Elsevier in Translational Oncology
- Vol. 54, 102329
Open AccessMIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies
- Open Access
- 12 November 2024
- Published by MDPI AG in Non-Coding RNA
- Vol. 10 (6) , 56
Androgen Receptor and Non-Coding RNAs’ Interaction in Renal Cell Carcinoma
Renal cell carcinoma (RCC), the most prevalent among the urogenital cancers, accounts for around 3% of new cancer cases worldwide. Significantly, the incidence of RCC has doubled in developed world countries, ranking it as the sixth most common cancer in males, who represent two-thirds of RCC cases. Males with RCC exhibit a higher mortality rate and tend to develop a more aggressive form of the disease than females. Sex-related risk factors, including lifestyle and biological variations, explain this difference. The androgen receptor (AR) oncogenic signaling pathway has been extensively studied among the biological factors that affect RCC. Recent advancements in high-throughput RNA sequencing techniques have underscored the significant roles played by noncoding-RNAs (ncRNAs), previously dismissed as “junk”. The oncogenic potential of AR is manifested through its dysregulation of the ncRNAs’ availability and function, promoting RCC tumorigenesis. This review offers a summary of the most recent findings on the role and molecular mechanisms of the AR in dysregulating the ncRNAs that play a role in the progression of RCC and the possibility of utilizing ncRNAs to target AR as a potential therapeutic strategy.
- 12 November 2024
- Published by MDPI AG in Non-Coding RNA
- Vol. 10 (6) , 56
Open AccessAndrogen Receptor and Non-Coding RNAs’ Interaction in Renal Cell Carcinoma
Renal cell carcinoma (RCC), the most prevalent among the urogenital cancers, accounts for around 3% of new cancer cases worldwide. Significantly, the incidence of RCC has doubled in developed world countries, ranking it as the sixth most common cancer in males, who represent two-thirds of RCC cases. Males with RCC exhibit a higher mortality rate and tend to develop a more aggressive form of the disease than females. Sex-related risk factors, including lifestyle and biological variations, explain this difference. The androgen receptor (AR) oncogenic signaling pathway has been extensively studied among the biological factors that affect RCC. Recent advancements in high-throughput RNA sequencing techniques have underscored the significant roles played by noncoding-RNAs (ncRNAs), previously dismissed as “junk”. The oncogenic potential of AR is manifested through its dysregulation of the ncRNAs’ availability and function, promoting RCC tumorigenesis. This review offers a summary of the most recent findings on the role and molecular mechanisms of the AR in dysregulating the ncRNAs that play a role in the progression of RCC and the possibility of utilizing ncRNAs to target AR as a potential therapeutic strategy.
- 13 October 2024
- Published by Springer Nature
- p. 229-265
CAR-NK/CAR-T Cells: Emerging Immunotherapy of Cancer
- 13 October 2024
- Published by Springer Nature
- p. 229-265
CAR-NK/CAR-T Cells: Emerging Immunotherapy of Cancer
- Open Access
- 18 September 2024
- Published by Springer Nature
- p. 545-557
Thyroid Cancer in the UAE
This chapter sheds light on thyroid cancer and its prevalence in the UAE. It entails the different histopathological classifications and molecular pathogenesis of thyroid malignant tumors, as well as their grading and staging. Since thyroid cancer incidence has increased in 2021 to become the second most prevalent cancer in the UAE, it is crucial to understand the incidence, mortality, and gender variations among the UAE population. It also describes the guidelines for the diagnosis and management of thyroid cancer.
- 18 September 2024
- Published by Springer Nature
- p. 545-557
Open AccessThyroid Cancer in the UAE
This chapter sheds light on thyroid cancer and its prevalence in the UAE. It entails the different histopathological classifications and molecular pathogenesis of thyroid malignant tumors, as well as their grading and staging. Since thyroid cancer incidence has increased in 2021 to become the second most prevalent cancer in the UAE, it is crucial to understand the incidence, mortality, and gender variations among the UAE population. It also describes the guidelines for the diagnosis and management of thyroid cancer.
- Open Access
- 17 April 2024
- Published by Elsevier in Translational Oncology
- Vol. 45
A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma
- 17 April 2024
- Published by Elsevier in Translational Oncology
- Vol. 45
Open AccessA Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma